Notice of Nominees for Directors
Tweet
Share
E-mail
1. Candidates for Directors (excluding Directors who Are Audit & Supervisory Committee Members)
Name | Current Position (As of | |
Reelection | Representative Director, Chairman of the Board | |
Reelection | Representative Director, President and CEO | |
Reelection | Representative Director, Executive Vice President, | |
Outside Reelection | Director, Senior Advisor, KDDI CORPORATION Director, Okinawa Cellular Telephone Company | |
Outside Reelection | Outside Director, Sumitomo Mitsui Financial Group, Inc. Outside Director, Kao Corporation Outside Director, Nippon Sheet Glass Company, Ltd | |
Outside Reelection | Outside Director, Kurita Water Industries Ltd. | |
Outside Reelection | Visiting Professor, Social Medicine, Research Administration Center and Medical Education Center, Saitama Medical University | |
Outside New Candidate | Chief Innovation Officer, Absci Corporation | |
Outside New Candidate | Non-Executive Director, BioMarin Pharmaceutical Inc. |
The current position of the candidates for outside Directors describes significant concurrent positions at other organizations pursuant to the Companies Act.
2. Candidates for Directors who Are Audit & Supervisory Committee Members
Name | Current Position (As of | |
Outside Reelection | Lawyer, Baba & Sawada Law Office Outside Director, GOLDWIN INC. |
The current position of the candidates for outside Directors describes significant concurrent positions at other organizations pursuant to the Companies Act.
3. | The Board of Directors as from |
Mark Enyedy (Outside Director) | |
Brief Biographies of New Candidates for Outside Director
Name:
Date of birth:
Resume, position and responsibilities at the Company:
Head of DG Cardiovascular Diseases, Hoechst Marion Roussel (current Sanofi S.A.) | |
Vice President, Head of DG Cardiovascular Diseases, Aventis (current Sanofi S.A.), | |
Global Head of Cardiovascular Research, Sanofi- Aventis (current Sanofi S.A.) | |
Senior Vice President, Head of Discovery Europe, Bayer HealthCare AG (current Bayer AG) | |
Head of Drug Discovery, Bayer Pharma AG (current Bayer AG) | |
Head of R&D and CSO, Shire plc | |
Chief Innovation Officer and CSO, Cyclerion Inc. (current Cyclerion Therapeutics Inc.) | |
February 2022 | Non-Executive Director, Centogene N.V. (current Crown LiquidationCo N.V.) |
Chief Innovation Officer, Absci Corporation, (present post) |
Name:
Date of birth:
Resume, position and responsibilities at the Company:
September 1990 | Associate, Palmer & Dodge |
Corporate Counsel, Genzyme Corporation (current Sanofi S.A.) | |
Vice President, Oncology, Business Development, Genzyme Corporation (current Sanofi S.A.) | |
President, Transplant, Oncology, and Multiple Sclerosis, Genzyme Corporation (current Sanofi S.A.) | |
Director, Chief Executive Officer, Proteostasis Therapeutics, Inc. (current Janssen Pharmaceutica N.V.) | |
Non-Executive Director, Fate Therapeutics, Inc. | |
Head of Business Unit, Internal Medicine, Shire plc | |
Head of Corporate Development, Shire plc | |
Director, President and Chief Executive Officer, ImmunoGen Inc. (current AbbVie Inc.) | |
Non-Executive Director, Keryx Biopharmaceuticals, Inc. (current Akebia Therapeutics, Inc.) | |
Non-Executive Director, LogicBio Therapeutics, Inc. (current Alexion Pharmaceuticals, Inc.) | |
Non-Executive Director, Ergomed Group Limited (present post) | |
Non-Executive Director, BioMarin Pharmaceutical Inc. (present post) |
About Astellas
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.
Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
View original content to download multimedia:https://www.prnewswire.com/news-releases/notice-of-nominees-for-directors-302448454.html
SOURCE Astellas Pharma Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Notice of Data Security Event
- Corgi Insurance appoints Joe Els as Head of Portfolio Risk
- Statement by Monty Deihl, Ocean Harvesters CEO, on Governor Spanberger's Amendments Restoring Funding for Virginia Chesapeake Bay Menhaden Study
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Genzyme/Sanofi-AventisSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
